Literature DB >> 15896434

Taurolidine lock: the key to prevention of recurrent catheter-related bloodstream infections.

Brian Jurewitsch1, Khursheed N Jeejeebhoy.   

Abstract

The literature shows that repeated courses of antibiotics and catheter removals in a subset of patients suffering from multiple catheter-related bloodstream infections (CRBSI), are unlikely to prevent recurrence. In acceding to preventative strategies, we report our application of the antimicrobial chemotherapeutic Taurolidine used as a daily flush solution in seven home TPN patients suffering from multiple episodes. A pretreatment infection rate of 10.8 infections per 1000 catheter days decreased to 0.8 after treatment.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15896434     DOI： 10.1016/j.clnu.2005.02.001

Source DB:  PubMed          Journal:  Clin Nutr        ISSN： 0261-5614            Impact factor:   7.324


  13 in total

Review 1.  Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review).

Authors:  Stella Baliou; Anthony M Kyriakopoulos; Demetrios A Spandidos; Vassilios Zoumpourlis
Journal:  Int J Oncol       Date:  2020-07-14       Impact factor: 5.650

2.  Minocycline-EDTA-Ethanol Antimicrobial Catheter Lock Solution Is Highly Effective In Vitro for Eradication of Candida auris Biofilms.

Authors:  Ruth A Reitzel; Joel Rosenblatt; Bahgat Z Gerges; Nylev Vargas-Cruz; Issam I Raad
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

3.  The Antiseptic and Antineoplastic Agent Taurolidine Modulates Key Leukocyte Functions.

Authors:  Yannick Wouters; Gina R H Mennen; René H M Te Morsche; Hennie M J Roelofs; Geert J A Wanten
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

4.  Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients.

Authors:  Ruediger Stendel; Louis Scheurer; Kathrin Schlatterer; Urs Stalder; Rolf W Pfirrmann; Ingo Fiss; Hanns Möhler; Laurent Bigler
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  New materials and devices for preventing catheter-related infections.

Authors:  Jean-François Timsit; Yohann Dubois; Clémence Minet; Agnès Bonadona; Maxime Lugosi; Claire Ara-Somohano; Rebecca Hamidfar-Roy; Carole Schwebel
Journal:  Ann Intensive Care       Date:  2011-08-18       Impact factor: 6.925

6.  Taurolidine lock is superior to heparin lock in the prevention of catheter related bloodstream infections and occlusions.

Authors:  Evelyn D Olthof; Michelle W Versleijen; Getty Huisman-de Waal; Ton Feuth; Wietske Kievit; Geert J A Wanten
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

7.  Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2.

Authors:  Ralf Kleef; Ralph Moss; A Marcell Szasz; Arthur Bohdjalian; Hans Bojar; Tibor Bakacs
Journal:  Integr Cancer Ther       Date:  2018-09-07       Impact factor: 3.279

8.  Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients.

Authors:  Arne Simon; Roland A Ammann; Gertrud Wiszniewsky; Udo Bode; Gudrun Fleischhack; Mette M Besuden
Journal:  BMC Infect Dis       Date:  2008-07-29       Impact factor: 3.090

Review 9.  Taurolidine lock solutions for the prevention of catheter-related bloodstream infections: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yong Liu; An-Qiang Zhang; Lin Cao; Hong-Tao Xia; Jun-Jie Ma
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

Review 10.  Intestinal failure: a review.

Authors:  Philip Allan; Simon Lal
Journal:  F1000Res       Date:  2018-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.